CHUGAI PHARMACEUTICAL CO., LTD.

Print

Translation

Feb 01, 2017

Organizational and Personnel Changes

TOKYO, February 1, 2017 - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that it will make the following personnel changes, effective March 23, 2017, organizational and personnel changes, effective April 1, 2017.

【Details of Organizational Changes】

Effective April 1, 2017

  • Project & Lifecycle Management Unit
    A rapid progress in science and technology such as life science and ICT will bring drastic changes to the society and the pharmaceutical industry. To take advantage of these changes as an opportunity for future growth, Science & Technology Intelligence Dept. will be newly established as an intelligence function which is equipped with high sensitivity, expertise and mobility.
  • Quality & Regulatory Compliance Unit
    Quality & Regulatory Compliance Unit will be reorganized aiming to lead the Chugai Group toward maintenance and improvement of global Quality Assurance System through strengthening the main three functions, “Compliance,” “Quality” and “Regulatory” which are essential to assure drug quality.
    • Quality & Regulatory Compliance Dept., Quality Assurance Dept. and Regulatory Affairs Audit Dept. will be restructured into Business Strategy & Compliance Dept., Quality Assurance Dept. and Quality Initiative Dept.
    • The function of regulatory affairs management of the Regulatory Affairs Dept. in the Project & Lifecycle Management Unit, and the function of the post-marketing regulatory affairs of the Quality & Regulatory Compliance Unit will be partly transferred and integrated into the Regulatory Intelligence & Management Dept. which is newly established in the Quality & Regulatory Compliance Unit.
    • Functions of each departments
      • Business Strategy & Compliance Dept.: To Plan the strategies for the Unit and promote the GxP* compliance at global level
      • Quality Assurance Dept.: To assure the quality of investigational drugs and the products regarding manufacturing and marketing process
      • Quality Initiative Dept.: To address the challenges regarding global quality system, process improvements to ensure quality assurance
      • Regulatory Intelligence & Management Dept.: To coordinate the regulatory intelligence activities, manage post-marketing regulatory affairs and medical information quality at global level

    * GxP: Good x Practice which means the standard practices and regulations for the range of operations such as “development,” “manufacturing” and “marketing” of the pharmaceuticals.

    e.g.) GCP (Good Clinical Practice; the standard practice for conducting clinical studies)

【Details of Personnel Changes】

Effective March 23, 2017

Directors

Name New Responsibilities Current Responsibilities
Yoichiro Ichimaru Director -
Christoph Franz Director -

- The appointment of Yoichiro Ishimaru and Christoph Franz as Directors is subject to approval at the 106th Annual General Meeting of Shareholders, which is scheduled to be convened on March 23, 2017.

- Yutaka Tanaka and Franz B. Humer, Currently Directors, are scheduled to retire from the Directors as of March 23, 2017 and Yutaka Tanaka is going to take the role of Senior Advisor (Full-time) from March 24, 2017.

Audit & Supervisory Board Member

Name New Responsibilities Current Responsibilities
Mamoru Togashi Audit & Supervisory
Board Member (Full-time)
Vice President
General Manager of Human Resources Supervisory Div.

- The appointment of Mamoru Togashi as an Audit & Supervisory Board Member is subject to approval at the 106th Annual General Meeting of Shareholders, which is scheduled to be convened on March 23, 2017.

- Kunitoshi Watanabe is scheduled to retire from the Audit & Supervisory Board Member as of March 23, 2017.

Vice President

Name New Responsibilities Current Responsibilities
Shinya Unno Senior Vice President
General Manager of Human Resources Supervisory Div.
General Affairs, Secretarial
In charge of Corporate Planning, Legal
Senior Vice President
General Affairs, Secretarial
In charge of Corporate Planning, Legal, Human Resources Supervisory Div.

Effective April 1, 2017

Vice Presidents

Name New Responsibilities Current Responsibilities
Shinya Unno Senior Vice President
General Manager of Human Resources Supervisory Div.
General Affairs, Secretarial
Senior Vice President
General Manager of Human Resources Supervisory Div.
General Affairs, Secretarial
In charge of Corporate Planning, Legal
Hisafumi Okabe Senior Vice President
In charge of Research, Clinical Translational Research
Senior Vice President
General Manager of Research Div.
In charge of Clinical Translational Research
Keiji Kono Senior Vice President
Global Health Policy, External Affairs
Vice President
Global Health Policy, External Affairs
Osamu Okuda Senior Vice President
General Manager of Corporate Planning Dept.
Vice President
General Manager of Corporate Planning Dept.
Junichi Ebihara Senior Vice President
General Manager of Legal Dept.
Vice President
General Manager of Legal Dept.

- Mitsuru Kikuchi, Senior Vice President, is scheduled to retire as of March 31, 2017 and is going to take the role of Senior Advisor (Full-time) from April 1, 2017.

Please see the PDF file about other personnel changes.

Contact:
For Media
Chugai Pharmaceutical Co., Ltd
Media Relations Group, Corporate Communications Dept.,
Koki Harada
Tel: +81-3-3273-0881
E-mail: pr@chugai-pharm.co.jp

For Investors
Chugai Pharmaceutical Co., Ltd
Investor Relations Group, Corporate Communications Dept.,
Toshiya Sasai
Tel: +81-3-3273-0554
E-mail: ir@chugai-pharm.co.jp

[ PDF 287KB]

To view PDF files,
you will need Adobe® Reader® which is available as a free download.

Close